{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:14:59Z","timestamp":1789748099654,"version":"4.0.1"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2024ZD0524000"],"award-info":[{"award-number":["2024ZD0524000"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017527","name":"Jiangsu Cancer Hospital","doi-asserted-by":"publisher","award":["YSZD202406"],"award-info":[{"award-number":["YSZD202406"]}],"id":[{"id":"10.13039\/501100017527","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004610","name":"Science and Technology Support Program of Jiangsu Province","doi-asserted-by":"publisher","award":["BG2024026"],"award-info":[{"award-number":["BG2024026"]}],"id":[{"id":"10.13039\/501100004610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["SJCX24_0786"],"award-info":[{"award-number":["SJCX24_0786"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.canlet.2025.218145","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:29:04Z","timestamp":1763346544000},"page":"218145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Current advances and future directions of combined ICIs and TILs in solid tumors"],"prefix":"10.1016","volume":"636","author":[{"given":"Yuxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-6200","authenticated-orcid":false,"given":"Qiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.218145_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13046-022-02264-x","article-title":"Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity","volume":"41","author":"Archilla-Ortega","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218145_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102942","article-title":"Viewing the immune checkpoint VISTA: landscape and outcomes across cancers","volume":"9","author":"Nishizaki","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2025.218145_bib3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2025.218145_bib4","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218145_bib5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ijc.35103","article-title":"Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition","volume":"156","author":"Forschner","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib9","article-title":"A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2025.218145_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","article-title":"Increasing cure rates of solid tumors by immune checkpoint inhibitors","volume":"12","author":"Ma","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008735","article-title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","volume":"12","author":"Betof Warner","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib13","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218145_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003499","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types","volume":"9","author":"Kverneland","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily--CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218145_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218145_bib17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218145_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semcancer.2022.03.014","article-title":"Immune checkpoint proteins: signaling mechanisms and molecular interactions in cancer immunotherapy","volume":"86","author":"Gaikwad","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2025.218145_bib19","article-title":"Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41423-023-01019-8","article-title":"Recent advancements in the B7\/CD28 immune checkpoint families: new biology and clinical therapeutic strategies","volume":"20","author":"Pulanco","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib21","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","article-title":"Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop","volume":"184","author":"Marangoni","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218145_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/eji.200737423","article-title":"CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell\/APC dwell times and calcium mobilization","volume":"38","author":"Schneider","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1471-4906(01)01888-9","article-title":"PD-1: an inhibitory immunoreceptor involved in peripheral tolerance","volume":"22","author":"Nishimura","year":"2001","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1084\/jem.20021752","article-title":"Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction","volume":"197","author":"Wang","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2025.218145_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib26","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2025.218145_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib28","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2025.218145_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13046-020-01818-1","article-title":"PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2\/Ras\/MAPK signalling in thyroid cancer cells","volume":"40","author":"Liotti","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218145_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.canlet.2025.218145_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","article-title":"Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors","volume":"22","author":"Catanzaro","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179958","article-title":"LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors","volume":"23","author":"Sauer","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.218145_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi7418","article-title":"LRIG1 engages ligand VISTA and impairs tumor-specific CD8(+) T cell responses","volume":"9","author":"Ta","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.682007","article-title":"BTLA-HVEM couple in health and diseases: insights for immunotherapy in lung cancer","volume":"11","author":"Demerle","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrd3463","article-title":"Ipilimumab","volume":"10","author":"Sondak","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2025.218145_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ph18030395","article-title":"Preclinical characterization of efficacy and pharmacodynamic properties of Finotonlimab, a humanized Anti-PD-1 monoclonal antibody","volume":"18","author":"Yao","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.canlet.2025.218145_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejca.2021.08.004","article-title":"Current strategies for intratumoural immunotherapy - beyond immune checkpoint inhibition","volume":"157","author":"Yuan","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114240","article-title":"The landscape of checkpoint inhibitors in oncology","volume":"209","author":"Haslam","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12916-022-02327-y","article-title":"Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR\/MSI-H gastric adenocarcinoma","volume":"20","author":"Wang","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.canlet.2025.218145_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13583","article-title":"Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary","volume":"51","author":"Rassy","year":"2021","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.canlet.2025.218145_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.955063","article-title":"Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures","volume":"13","author":"Hossain","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib43","first-page":"42","article-title":"Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma","volume":"7","author":"Jalil","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.canlet.2025.218145_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","article-title":"Turning cold tumors hot: from molecular mechanisms to clinical applications","volume":"43","author":"Zhang","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib45","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies","volume":"40","author":"Passaro","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib46","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.218145_bib47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.218145_bib48","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2326-6066.CIR-22-0326","article-title":"Coexisting alterations of MHC class I antigen presentation and IFNgamma signaling mediate acquired resistance of melanoma to Post-PD-1 immunotherapy","volume":"10","author":"Nielsen","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2025.218145_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123729","article-title":"Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy","volume":"12","author":"Boyero","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2025.218145_bib51","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling Regulates a Multigenic Resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218145_bib52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib53","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib54","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/1078-0432.CCR-23-2457","article-title":"Objective analysis and clinical significance of the spatial tumor-infiltrating lymphocyte patterns in non-small cell lung cancer","volume":"30","author":"Lopez de Rodas","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218145_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010207","article-title":"Art of TIL immunotherapy: sitc's perspective on demystifying a complex treatment","volume":"13","author":"Turcotte","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib57","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.218145_bib58","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.trecan.2024.04.003","article-title":"Lifileucel: the first cellular therapy approved for solid tumours","volume":"10","author":"Julve","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib59","article-title":"TIL therapy in lung cancer: current progress and perspectives","volume":"11","author":"Hu","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2025.218145_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011066","article-title":"CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion","volume":"13","author":"Rossetti","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib61","doi-asserted-by":"crossref","first-page":"S610","DOI":"10.1016\/j.jtct.2024.04.015","article-title":"Defining the quality attributes for tumor-infiltrating lymphocyte medicinal products","volume":"31","author":"Lievense","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.canlet.2025.218145_bib62","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib63","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12916-021-02006-4","article-title":"Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors","volume":"19","author":"Wang","year":"2021","journal-title":"BMC Med."},{"key":"10.1016\/j.canlet.2025.218145_bib64","doi-asserted-by":"crossref","DOI":"10.4110\/in.2024.24.e16","article-title":"Beyond the CAR T cells: TIL therapy for solid tumors","volume":"24","author":"Singh","year":"2024","journal-title":"Immune Netw"},{"key":"10.1016\/j.canlet.2025.218145_bib65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","article-title":"Engineered T cell therapy for viral and non-viral epithelial cancers","volume":"41","author":"Norberg","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.218145_bib66","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218145_bib67","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218145_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000668","article-title":"Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma","volume":"8","author":"Borch","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040743","article-title":"Adoptive immunotherapy beyond CAR T-Cells","volume":"13","author":"Titov","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2025.218145_bib70","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/2326-6066.CIR-24-0857","article-title":"The bidirectional interplay between T cell-based immunotherapies and the tumor microenvironment","volume":"13","author":"Pherez-Farah","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2025.218145_bib71","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/s12967-023-04329-7","article-title":"Perspectives in immunotherapy: meeting report from immunotherapy bridge (Naples, November 30th-December 1st, 2022)","volume":"21","author":"Ascierto","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2025.218145_bib72","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib73","article-title":"Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A \u221702:01 patients with advanced soft tissue sarcoma","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2025.218145_bib74","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","article-title":"Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy","volume":"186","author":"Dolton","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218145_bib75","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological malignancies: advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2025.218145_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001749","article-title":"Therapeutic depletion of CCR8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy","volume":"9","author":"Van Damme","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib77","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.apsb.2021.08.020","article-title":"Emerging role of natural products in cancer immunotherapy","volume":"12","author":"Dong","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2025.218145_bib78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/intimm\/dxaa046","article-title":"Immune metabolism in PD-1 blockade-based cancer immunotherapy","volume":"33","author":"Kumar","year":"2021","journal-title":"Int. Immunol."},{"key":"10.1016\/j.canlet.2025.218145_bib79","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2025.218145_bib80","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1200\/JCO.2012.46.6441","article-title":"Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma","volume":"31","author":"Dudley","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib81","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.molonc.2015.10.018","article-title":"Tumor-infiltrating lymphocytes for the treatment of metastatic cancer","volume":"9","author":"Geukes Foppen","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib82","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7890985","article-title":"Retrospective analysis of adoptive TIL therapy plus Anti-PD1 therapy in patients with chemotherapy-resistant metastatic Osteosarcoma","volume":"2020","author":"Zhou","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.canlet.2025.218145_bib83","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib84","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1158\/1078-0432.CCR-21-4413","article-title":"An autologous dendritic cell vaccine promotes anticancer immunity in patients with ovarian cancer with low mutational burden and cold tumors","volume":"28","author":"Fucikova","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218145_bib85","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2025.218145_bib86","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cmet.2016.10.015","article-title":"Lactate wreaks havoc on tumor-infiltrating T and NK cells","volume":"24","author":"Scott","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.canlet.2025.218145_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk7399","article-title":"Activation and antitumor immunity of CD8(+) T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid","volume":"16","author":"Liu","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2025.218145_bib88","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.21.02010","article-title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer","volume":"40","author":"Park","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib89","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/2326-6066.CIR-22-0795","article-title":"Regional variation in the tumor microenvironment, immune escape and prognostic factors in breast cancer in Sub-Saharan Africa","volume":"11","author":"Bauer","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2025.218145_bib90","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.2019-0611","article-title":"Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes","volume":"25","author":"Loupakis","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2025.218145_bib91","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.lungcan.2021.01.013","article-title":"Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study","volume":"153","author":"Hashemi","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib92","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-22-2103","article-title":"Combination nivolumab, CD137 agonism, and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic Melanoma","volume":"28","author":"Hall","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218145_bib93","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib94","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","article-title":"Tumor-Infiltrating lymphocyte therapy in melanoma: facts to the future","volume":"29","author":"Betof Warner","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218145_bib95","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12916-024-03420-0","article-title":"IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer","volume":"22","author":"Guo","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.canlet.2025.218145_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003887","article-title":"Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen","volume":"10","author":"Guo","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib97","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218145_bib98","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1158\/0008-5472.CAN-20-2300","article-title":"T cells expanded from PD-1(+) peripheral blood lymphocytes share more clones with paired tumor-infiltrating lymphocytes","volume":"81","author":"Li","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218145_bib99","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ccell.2023.09.005","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.218145_bib100","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","article-title":"Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment: a systematic review and meta-analysis","volume":"159","author":"Du","year":"2023","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.canlet.2025.218145_bib101","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cell.2019.08.012","article-title":"Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence","volume":"179","author":"Harel","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218145_bib102","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ccell.2020.05.004","article-title":"Multi-phenotype CRISPR-Cas9 screen identifies p38 kinase as a target for adoptive immunotherapies","volume":"37","author":"Gurusamy","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.218145_bib103","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","article-title":"Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy","volume":"24","author":"Chamberlain","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.canlet.2025.218145_bib104","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-024-00561-1","article-title":"CRISPR-Cas9 applications in T cells and adoptive T cell therapies","volume":"29","author":"Chen","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.canlet.2025.218145_bib105","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/curroncol30010098","article-title":"Immune checkpoint glycoproteins have polymorphism: are monoclonal antibodies too specific?","volume":"30","author":"Jalalizadeh","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.canlet.2025.218145_bib106","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1053\/j.gastro.2017.06.017","article-title":"Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas","volume":"153","author":"Zhou","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2025.218145_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914780","article-title":"Combined or sequential treatment with immune checkpoint inhibitors and Car-T cell therapies for the management of haematological malignancies: a systematic review","volume":"24","author":"Perez-Moreno","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.218145_bib108","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12943-023-01926-4","article-title":"Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1\/PD-L1 blockade in the clinical spectrum of lung cancer","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110873","article-title":"Tumor-infiltrating lymphocytes: warriors fight against tumors powerfully","volume":"132","author":"Lin","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2025.218145_bib110","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2020.09.048","article-title":"Detecting Tumor antigen-specific T cells via interaction-dependent fucosyl-biotinylation","volume":"183","author":"Liu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218145_bib111","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41416-023-02181-6","article-title":"Immune checkpoint inhibitor combinations-current and emerging strategies","volume":"128","author":"Walsh","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113099","article-title":"A multi-task deep learning model based on comprehensive feature integration and self-attention mechanism for predicting response to anti-PD1\/PD-L1","volume":"142","author":"Wang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2025.218145_bib113","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006822","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","volume":"12","author":"Amaria","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218145_bib114","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11764-023-01452-8","article-title":"\"One more chance to survive\": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care","volume":"19","author":"Egeler","year":"2025","journal-title":"J Cancer Surviv"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:24:50Z","timestamp":1773807890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525007177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":114,"alternative-id":["S0304383525007177"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218145","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current advances and future directions of combined ICIs and TILs in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218145"}}